Rheumatic diseases, glucocorticoid treatment and bone mass: Recent developments

M. Mazzantini, Nancy E Lane

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume18
Issue number5 SUPPL. 21
StatePublished - 2000
Externally publishedYes

Fingerprint

Rheumatic Diseases
Glucocorticoids
Bone and Bones
Osteoporotic Fractures
Osteoporosis
Guidelines
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Glucocorticoids
  • Osteoporosis
  • Prevention
  • Rheumatic diseases
  • Treatment

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Rheumatic diseases, glucocorticoid treatment and bone mass : Recent developments. / Mazzantini, M.; Lane, Nancy E.

In: Clinical and Experimental Rheumatology, Vol. 18, No. 5 SUPPL. 21, 2000.

Research output: Contribution to journalArticle

@article{646fb5710b3d43349ba86767331c3c2b,
title = "Rheumatic diseases, glucocorticoid treatment and bone mass: Recent developments",
abstract = "Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.",
keywords = "Glucocorticoids, Osteoporosis, Prevention, Rheumatic diseases, Treatment",
author = "M. Mazzantini and Lane, {Nancy E}",
year = "2000",
language = "English (US)",
volume = "18",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5 SUPPL. 21",

}

TY - JOUR

T1 - Rheumatic diseases, glucocorticoid treatment and bone mass

T2 - Recent developments

AU - Mazzantini, M.

AU - Lane, Nancy E

PY - 2000

Y1 - 2000

N2 - Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.

AB - Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.

KW - Glucocorticoids

KW - Osteoporosis

KW - Prevention

KW - Rheumatic diseases

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033769119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033769119&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033769119

VL - 18

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5 SUPPL. 21

ER -